Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

• Status: Completed
• Trial end date: 2008-12-01

Summary

Multicenter, open-label, dose-ranging study in two parts: maximum tolerated dose (MTD) segment (the first 28-day course of MP 470) followed by long-term safety segment.

MTD segment: follows standard oncology phase-I design; within-patient dose level adjustments prohibited; each patient participates in one of three stages:

1. Accelerated Titration Stage

2. Dose Escalation/De-Escalation Stage

3. Dose Confirmation Stage

• Phase: Phase 1

Details

• Lead Sponsor: Astex Pharmaceuticals; Astex Pharmaceuticals, Inc.